↓ Skip to main content

Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry

Overview of attention for article published in Clinical Rheumatology, February 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
6 X users

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry
Published in
Clinical Rheumatology, February 2016
DOI 10.1007/s10067-016-3191-3
Pubmed ID
Authors

Laura M. M. Steunebrink, Harald E. Vonkeman, Peter M. ten Klooster, Monique Hoekstra, Piet L. C. M. van Riel, Mart A. F. J. van de Laar

Abstract

Despite considerable evidence on the efficacy and safety of early aggressive treat-to-target (T2T) strategies in early rheumatoid arthritis (RA), a proportion of patients still fail to reach remission. The goal of this study is to examine remission rates and predictors of remission in a real life T2T cohort of consecutive patients with a recent diagnosis of RA. Baseline demographics, clinical, laboratory and patient-reported variables and 1-year follow-up disease activity data were used from patients with early RA included in the DREAM remission induction cohort II study. Survival analyses and simple and multivariable logistic regression analyses were used to examine remission rates and significant predictors of achieving remission. A total of 137 recently diagnosed consecutive RA patients were available for this study. During the first year after inclusion, DAS28 remission was achieved at least once in 77.2 % of the patients and the median time to first remission was 17 weeks. None of the examined baseline variables were robustly associated with achieving remission within 1 year and in the multivariable analysis only lower ESR (p = 0.005) remained significantly associated with achieving fast remission within 17 weeks. During the first year of their disease a high proportion of recently diagnosed RA patient achieved remission, with only a small percentage of patients needing bDMARD therapy. Combined with the absence of baseline predictors of remission, this suggests that clinicians in daily clinical practice may focus on DAS28 scores only, without needing to take other patients characteristics into account.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 2%
Colombia 1 2%
Canada 1 2%
Unknown 43 93%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 17%
Student > Ph. D. Student 7 15%
Other 5 11%
Professor 5 11%
Student > Bachelor 4 9%
Other 12 26%
Unknown 5 11%
Readers by discipline Count As %
Medicine and Dentistry 15 33%
Pharmacology, Toxicology and Pharmaceutical Science 5 11%
Psychology 4 9%
Biochemistry, Genetics and Molecular Biology 3 7%
Nursing and Health Professions 3 7%
Other 7 15%
Unknown 9 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 December 2016.
All research outputs
#7,418,990
of 22,854,458 outputs
Outputs from Clinical Rheumatology
#1,128
of 3,006 outputs
Outputs of similar age
#125,095
of 397,376 outputs
Outputs of similar age from Clinical Rheumatology
#5
of 41 outputs
Altmetric has tracked 22,854,458 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,006 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 397,376 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.